SecBot SecBot
8-K ·Filed May 13, 2026

ABUS

Arbutus Biopharma Corp
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001171843-26-003346
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The $178.7M Moderna settlement payment expected in July 2026 transforms the balance sheet, cash will rise to ~$274M, or ~$1.39/share. Watch for capital return plans (management flagged evaluation in Q3 2026). The FDA Fast Track for imdusiran is a positive regulatory catalyst, but the stock's re-rating depends on execution of the Pfizer/BioNTech LNP litigation, which remains unresolved.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025, driven by $178.7M in license revenue from Genevant related to the Moderna settlement. Excluding this one-time item, core operating expenses fell sharply to $10.2M from $27.5M, reflecting prior restructuring. The stock will move on the visibility of the $178.7M cash receipt in July 2026 and the FDA Fast Track designation for imdusiran, but the underlying business remains a pre-revenue clinical-stage biotech.

Key Financial Metrics

EPS
$0.87
est −$0.06 · +1550.0%
Revenue
$179.1M
est $1.5M · +11841.7% · +10055.0% YoY
Rating
strong beat

Key Facts

  • Q1 2026 total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
  • GAAP net income $169.7M ($0.87 diluted EPS) vs net loss $24.5M ($-0.13) YoY
  • Cash and marketable securities $95.2M at March 31, 2026, up from $91.5M at Dec 31, 2025
  • Company expects to receive ~$178.7M from Moderna settlement in July 2026
  • FDA granted Fast Track designation for imdusiran (chronic hepatitis B) in April 2026
  • R&D expenses fell to $4.1M from $9.0M YoY; no restructuring costs vs $12.4M in Q1 2025
  • Operating cash burn $8.1M in Q1 2026, improved from $13.4M in Q1 2025
  • 196.9M shares outstanding as of March 31, 2026

Financial Impact

Q1 2026 net income of $169.7M vs consensus loss of $0.06 EPS; revenue of $179.1M vs $1.5M consensus. The $178.7M license receivable from Genevant is a one-time event, but adds ~$0.91 per share to book value.

revenuenet incomecash positionoperating expenses

Risk Factors

  • Core business is pre-revenue, ongoing operating cash burn of ~$8M/quarter
  • Pfizer/BioNTech LNP litigation outcome uncertain; no settlement timeline
  • Contingent $1.3B Moderna payment depends on appellate ruling on Section 1498
  • Imdusiran still in Phase 2a; no guarantee of regulatory approval or commercial success

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-003346
Document: f8k_051226.htm0001171843-26-003346
Document: 0001171843-26-003346-index-headers.html0001171843-26-003346
Document: 0001171843-26-003346-index.html0001171843-26-003346
Document: 0001171843-26-003346.txt0001171843-26-003346
8-K Data (Synthetic)0001171843-26-003346

Track record

25 reports on ABUS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026